OUR VISION IS TO REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES WORLDWIDE.

Introduction

Fungal diseases are neglected worldwide by public health authorities. GAFFI efforts are directed at:
  • Identifying and publicising gaps in diagnostics and treatments for fungal diseases,
  • Consulting on how services could be improved through facilitating training, encouraging companies to expand their markets and recommending improvements in infrastructure,
  • Estimating the burden of serious fungal diseases, country by country. Over 65 countries with a population >1 million have been addressed, and many are published (view),
  • Develop, implement and evaluate country-wide diagnostic programs. Guatemala (fungal infections in AIDS) is the first (view)
  • Influence national and international agencies to ‘adopt’ fungal diseases alongside existing programs including TB, microbiology, AMR, NTDs and incorporation of key generic antifungals onto the WHO Essential Medicines List.
  • Focussed diagnostic improvements for GAFFI’s priority diseases.
Globally, over 300 million people of all ages suffer from a serious fungal infection every year. Of these over 1.66 million people are estimated to die. Most serious fungal infections are ‘hidden’ because of other health problems. The objective: 95% of patients with serious fungal infections are diagnosed and treated.
GAFFI’s President David Denning summarises GAFFI's achievements over the last 4 years. See the new GAFFI brochure.   El presidente de GAFFI  David Denning, ha resumido el trabajo de GAFFI  en los últimos 4 años. Puede ver el nuevo folleto en español.

“The incidence of cryptococcal meningitis remains high despite record levels of antiretroviral therapy rollout in Boswana. "Cryptococcal meningitis requires a rethink – only 40% of these patients are still alive at 12 months". Dr Joe Jarvis, EMBO Mycoses in AIDS meeting in Cape Town. ”